Mcdonald Partners LLC Reduces Position in AbbVie Inc. $ABBV

Mcdonald Partners LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 14.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,589 shares of the company’s stock after selling 3,327 shares during the quarter. AbbVie makes up 1.4% of Mcdonald Partners LLC’s portfolio, making the stock its 15th biggest position. Mcdonald Partners LLC’s holdings in AbbVie were worth $4,536,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of AbbVie during the 2nd quarter valued at approximately $4,288,200,000. Laurel Wealth Advisors LLC increased its stake in shares of AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after buying an additional 5,675,095 shares during the last quarter. Vanguard Group Inc. raised its holdings in AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in AbbVie by 169.3% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after acquiring an additional 2,969,202 shares during the last quarter. Finally, Raymond James Financial Inc. grew its holdings in AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after acquiring an additional 2,753,312 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Down 0.4%

Shares of NYSE ABBV opened at $233.44 on Wednesday. The firm’s 50-day moving average price is $224.56 and its two-hundred day moving average price is $223.66. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock has a market capitalization of $412.76 billion, a P/E ratio of 98.92, a P/E/G ratio of 0.81 and a beta of 0.34.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive topline Phase 3 AFFIRM results for risankizumab (SKYRIZI) subcutaneous induction in moderately to severely active Crohn’s disease, showing superiority vs. placebo and no new safety signals — a material clinical win that expands AbbVie’s immunology franchise and supports future uptake. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: FDA approval for an oral combination of VENCLEXTA and acalabrutinib in previously untreated CLL adds an approved hematology-oncology option to AbbVie’s portfolio, supporting long-term revenue diversification in oncology. AbbVie’s New Data And Approval Test Growth And Valuation Story
• Positive Sentiment: Planned $380M investment to build two new active pharmaceutical ingredient manufacturing facilities in Illinois signals capacity expansion, vertical integration and potential margin/production benefits over time. Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now?
• Positive Sentiment: Multiple analyst/outlet pieces highlight AbbVie’s attractive dividend yield and steady payout growth, which can support investor demand from income-oriented funds and long-term investors. Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
• Neutral Sentiment: Management will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 10), providing another opportunity for guidance clarity and incremental investor Q&A but not an immediate catalyst. AbbVie to Present at the Leerink Partners Global Healthcare Conference
• Neutral Sentiment: Mentions in industry reports on continuous manufacturing and market trends underscore structural tailwinds for pharma manufacturing efficiency but are longer‑term and indirect for AbbVie’s near-term stock moves. Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players – AbbVie…
• Negative Sentiment: Despite the positive headlines, the stock is down today — likely reflecting short‑term profit-taking and a stretched valuation/PE that makes the name sensitive to market rotation and earnings expectations in the near term.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target for the company. BMO Capital Markets restated an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a research note on Thursday, January 15th. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Finally, Evercore decreased their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.15.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.08% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.